Ajanta Pharma Limited

Equities

AJANTPHARM

INE031B01049

Pharmaceuticals

Market Closed - NSE India S.E. 07:43:46 2024-04-26 am EDT 5-day change 1st Jan Change
2,194 INR +2.50% Intraday chart for Ajanta Pharma Limited +5.18% +5.27%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Ajanta Pharma Posts Gains in Fiscal Q3 Consolidated Net Profit MT
Transcript : Ajanta Pharma Limited, Q3 2024 Earnings Call, Jan 31, 2024
Ajanta Pharma Limited Approves Second Interim Dividend for the Year Fiscal Year 2024, Payable on or After 19th February 2024 CI
Ajanta Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Ajanta Pharma Board to Consider Second Interim Dividend for Fiscal 2024 MT
Ajanta Pharma Limited Provides Earnings Guidance for the Full Year of Fiscal 2024 CI
Transcript : Ajanta Pharma Limited, Q2 2024 Earnings Call, Oct 31, 2023
Ajanta Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Ajanta Pharma Gets US FDA Nod for Topiramate Extended-Release Capsules MT
Ajanta Pharma Limited Receives Final Approval from US FDA for Topiram Extended Release Capsules CI
Ajanta Pharma Logs Increase in Fiscal Q1 Consolidated Profit MT
Transcript : Ajanta Pharma Limited, Q1 2024 Earnings Call, Jul 27, 2023
Ajanta Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Ajanta Pharma Board to Consider Interim Dividend for Fiscal 2024 MT
Ajanta Pharma Limited Confirms the Interim Dividend for the Year Ended 31 March 2023 CI
Ajanta Pharma Gets No Observations After US FDA's Inspection of API Facility in Hyderabad, India MT
Transcript : Ajanta Pharma Limited, Q4 2023 Earnings Call, May 05, 2023
Ajanta Pharma Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Ajanta Pharma Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Tranche Update on Ajanta Pharma Limited's Equity Buyback Plan announced on March 10, 2023. CI
Ajanta Pharma Limited's Equity Buyback announced on March 10, 2023, has closed with 2,210,500 shares, representing 1.73% for ¥3,149.96 million. CI
Ajanta Pharma Board OKs Up To INR3.2 Billion Share Buyback MT
Ajanta Pharma Limited announces an Equity Buyback for 2,210,500 shares, representing 1.73% for INR 3,890 million. CI
Ajanta Pharma Limited authorizes a Buyback Plan. CI
INDIA STOCKS-Indian shares open lower on rate fears after Powell's testimony RE
Chart Ajanta Pharma Limited
More charts
Ajanta Pharma Limited is an India-based specialty pharmaceutical company. The Company provides a comprehensive range of specialty branded generic products targeting a broad range of chronic and acute therapies. The Company is engaged in the manufacturing and sale of branded generic and generic pharmaceutical products. It has a wide range of therapeutic segments, such as cardiology, anti-diabetes, ophthalmology, dermatology, antibiotic, anti-malarial, pain, respiratory, gynecology, pediatric and general health products. Its branded generics business is spread across India, the rest of Asia, and Africa. Its business also consists of two verticals: United States generics and institutional business in Africa. Its ophthalmology products include Bimat (anti glaucoma), Nepaflam (anti-inflammatory), Softdrops (lubricant), and Olopat (anti-allergic). The Company's cardiology products include MET XL, Atorfit CV, Antihypertensive Cinod, Rosutor Gold, Dapalex and Vilatin.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
2,194 INR
Average target price
2,271 INR
Spread / Average Target
+3.54%
Consensus
  1. Stock Market
  2. Equities
  3. AJANTPHARM Stock
  4. News Ajanta Pharma Limited
  5. Ajanta Pharma Posts Gains in Fiscal Q3 Consolidated Net Profit